Monday, June 29, 2009

A meteor has hit endocrinology!!

Let's get the team commenting on this study in diabetologia!
"The European Association for the Study of Diabetes (EASD) today makes an urgent call for more research into a possible link between use of insulin glargine (an insulin analogue, brand name Lantus) and increased risk of cancer, following evidence from studies in Germany, Sweden and Scotland. However, until this further research becomes available, these experts are stressing that patients with diabetes taking Lantus should continue to do so, although some might wish to consider alternative types of insulin. The studies are reported in Diabetologia (the journal of EASD)."


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.